Vincenzo Cassibba

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Renato Bassan, Orietta Spinelli, Elena Oldani et al. · Blood · 2009 · 430 citations · Full text

Medicine, Oncology, Chemotherapy +13

Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups

Sergio Amadori, Stefan Suciu, Roberto Stasi et al. · Leukemia · 2005 · 90 citations

Medicine, Oncology, Pharmacology +13

Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation

Anna Locasciulli, Benedetto Bruno, Emilio Paolo Alessandrino et al. · Bone Marrow Transplantation · 2003 · 76 citations

Medicine, Hematology, Infectious Diseases +17

High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program

Tamara Intermesoli, Alessandro Rambaldi, Giuseppe Rossi et al. · Haematologica · 2013 · 48 citations · Full text

Medicine, Oncology, Pharmacology +14

Relationship between Daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia.

Giuseppe Todeschini, Vittorio Meneghini, Giovanni Pizzolo et al. · PubMed · 1994 · 35 citations

Medicine, Oncology, Pharmacology +13